Ranolazine Contraindications in Chronic Kidney Disease
Introduction to Contraindications
- The American College of Cardiology recommends that ranolazine should not be used in patients with chronic kidney disease (CKD) undergoing hemodialysis due to its contraindication when the glomerular filtration rate (GFR) is <30 ml/min/1.73 m² 1
Pharmacokinetic Concerns
- Ranolazine undergoes extensive hepatic metabolism via cytochrome P450 and is primarily excreted through the kidneys, with plasma levels increasing by 50-60% in patients with moderate renal or hepatic impairment 1
- In patients with GFR <30 ml/min/1.73 m², excessive drug accumulation poses a risk of further complications 1
Clinical Risks
- Patients with CKD undergoing hemodialisis have very low GFR (usually <15 ml/min/1.73 m²), which is below the safety threshold 1
- The use of ranolazine in this population can lead to hazardous drug accumulation and increase the risk of serious side effects 1
Alternative Antiangina Therapies
- Beta-blockers: can be used in patients with CKD undergoing hemodialysis without contraindications, although dose adjustments may be necessary for some agents 1
- Calcium channel blockers: are safe to use without specific contraindications in CKD 1
- Nitrates: can be used safely in patients with CKD undergoing hemodialysis 1
Special Considerations for Hemodialysis Patients
- Vasodilating beta-blockers like carvedilol and nebivolol can improve insulin sensitivity, which is beneficial if the patient also has diabetes 1
- For patients with bradycardia or hypotension, calcium channel blockers or nitrates are preferred due to their hemodynamic profile 1